Telix boosts in-house ra­dio­phar­ma man­u­fac­tur­ing; Dy­navax im­proves vac­cine pro­duc­tion costs

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Telix Phar­ma­ceu­ti­cals is ac­quir­ing Texas-based ra­dio­phar­ma and bio­con­ju­gate com­pa­ny IsoTher­a­peu­tics in a deal that in­cludes $8 mil­lion up front. This will bring man­u­fac­tur­ing in-house for Aus­tralian biotech Telix, ac­cord­ing to a Tues­day re­lease.

Dy­navax Tech­nolo­gies tout­ed its de­creas­ing man­u­fac­tur­ing costs per unit for its he­pati­tis B vac­cine HEP­LISAV-B, at­tribut­ing this to “a num­ber of in­vest­ments in man­u­fac­tur­ing,” said CFO Kel­ly Mac­Don­ald dur­ing an in­vestor call on Feb. 22. The com­pa­ny made in­vest­ments at its anti­gen man­u­fac­tur­ing fa­cil­i­ty in Düssel­dorf, Ger­many, which has helped the com­pa­ny to im­prove its yield of HEP­LISAV-B.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.